Cardiff Oncology Corp - Rasio nilai perusahaan marang dodolan CRDF

Simbol resmi perusahaan Cardiff Oncology Inc. (CRDF)

High R&D costs and dependence on Onvansertib trials create volatility, which is mitigated by partnerships with clinics fighting colorectal cancer. The price-to-sales multiple on the GURU.Markets terminal line chart demonstrates that the current level is 64142.86. This trend reflects joint testing with physicians to implement new therapy standards for colorectal tumors for Cardiff Oncology, Inc. (CRDF).

Cardiff Oncology (CRDF): Nilai perusahaan marang pendapatan saka 23.11.2025 nganti 20.11.2026

Cardiff Oncology - rincian analitis lan metrik utama (CRDF)

Pambiji fundamental perusahaan:CRDF, Cardiff Oncology Corp
Produk sing diprodhuksi cardiffoncology.com

This indicator assesses the total enterprise value, including net debt, relative to the volume of generated sales. The metric allows for the identification of overpayment for an asset regardless of its debt load. By analyzing the current EV/Sales level, an investor identifies anomalies in capitalization dynamics. For Cardiff Oncology, Inc. (CRDF), this is critical, as future revenue from targeted drugs depends on insurance reimbursements. The stability of the chart confirms market expectations regarding the commercialization of cancer therapy.

Analisis pesaing

Multiplikator nilai perusahaan marang pendapatan Incyte Corporation|HCM (HUTCHMED Corp) - Nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang dodolan Nuvation Pharma NUVB|Nilai perusahaan marang pendapatan DAWN|Multiplikator nilai perusahaan marang pendapatan Monopar Therapeutics MNPR|Nilai perusahaan marang pendapatan INBX (Inhibrx Biosciences)|IMAB (I-Mab Inc.) - Nilai bisnis marang pendapatan|Fennec Pharmaceuticals - Nilai perusahaan marang pendapatan|Koefisien nilai perusahaan marang pendapatan HRTX (Heron Therapeutics Inc)|Nuvectis - Multiplikator EV/Sales|Nilai bisnis marang pendapatan CHRS (Coherus BioSciences Inc.)|CRBP: Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan beyondspringpharma.com (BYSI)|Rasio nilai perusahaan marang pendapatan bioatla.com|LIXT: Nilai bisnis marang pendapatan|Multiplikator EV/Sales CTXR|Multiplikator EV/Sales Cellectar Corp (CLRB)|Rasio nilai perusahaan marang pendapatan BioLineRx Corp BLRX|CANF (Can-Fite BioPharma Ltd.) - Nilai perusahaan marang volume dodolan|APRE: Nilai perusahaan marang pendapatan|Multiplikator nilai perusahaan marang pendapatan Kazia Therapeutics Limited|Silexion Therapeutics Corp (SLXN) - Rasio nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan NCNA|CMRX (Chimerix, Inc.) - Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Cyclacel Pharmaceuticals CYCC|G1 Therapeutics Inc. (GTHX) - Nilai bisnis marang pendapatan|KRON - Multiplikator nilai perusahaan marang pendapatan|Kintara Therapeutics, Inc. - Nilai perusahaan marang pendapatan|Koefisien nilai perusahaan marang pendapatan ONCT (Oncternal)|Portage Biotech Corp - Multiplikator EV/Sales